EP3773533A1 — Liquid dosage forms of cinacalcet or salt thereof

USPTO Abstract

Cinacalcet is approved and marketed as hydrochloride salt in a solid dosage form indicated for the treatment of secondary hyperparathyroidism resulting from chronic kidney disease and for the treatment of hypercalcemia in patients with either parathyroid card noma or hyperparathyroidism. Current marketed products are not allowed to be divided and to be taken whole during administration. Patients having swallowing difficulty may not show adherence to such regimen. The present invention therefore provides liquid dosage forms of Cinacalcet or pharmaceutically acceptable salt thereof.